![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
2.83 | 1.55% | 185.00 | 186.85 | 182.11 | 183.85 | 6,948,834 | 01:00:00 |
By Colin Kellaher
AbbVie said Wednesday that a Phase 2 study of its experimental drug telisotuzumab-vedotin, or teliso-V, showed a reduction in disease in patients with a type of non-small cell lung cancer.
AbbVie said the study evaluating teliso-V in patients with c-Met protein overexpression, epidermal growth factor receptor wild type, advanced/metastatic nonsquamous non-small cell lung cancer showed a reduction in the disease in 35% and 23% of c-Met High and c-Met Intermediate patients, respectively.
In addition, the company said the study results showed that patients' tumors continued to respond to treatment for a median duration of nine months and 7.2 months across c-Met High and c-Met Intermediate patients, respectively, with the patients surviving for a median of 14.6 months and 14.2 months, respectively.
Lung cancer is the leading cause of cancer death around the world, with non-small cell lung cancer accounting for about 85% of all cases.
AbbVie said C-Met protein overexpression is found in about 25% of advanced epidermal growth factor receptor wild type non-small cell lung cancer patients and is associated with a poor prognosis.
The North Chicago, Ill.-based biopharmaceutical company said it plans to hold talks with global health authorities on the potential to support an accelerated approval of teliso-V.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 29, 2023 09:57 ET (14:57 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions